Vogenx closed at $19.56 on Nov 2, down 3.41%, 42.7% below its highest close since Sep 11. Volume of 96.8K shares was 1.01× its 20-day average (close to normal).
Split-adjusted performance: +7.3% over one month.
Short interest was 38.3K shares at the Oct 15 settlement, up 42.7% from the prior report (0.4% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 419 companies (100 = best)
Industry medians: 6-month return −24.8%, revenue growth +6.4%, net margin −36.2%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| VOGXVogenx | $19.56 | −3.41% | — | — | — | — | $290.6M | |
| CGCCanopy Growth | $0.6885 | +5.52% | −37.4% | +7.8% | −18.0% | — | $291.3M | Compare |
| BNTCBenitec Biopharma | $8.42 | −3.66% | −30.9% | — | — | — | $293.8M | Compare |
| PRLDPrelude Therapeutics Incorporated | $3.75 | −3.35% | −20.9% | — | −244.1% | — | $299.3M | Compare |
| FULCFulcrum Therapeutics | $3.69 | −0.67% | −47.5% | — | — | — | $281.5M | Compare |
| ENTAEnanta Pharmaceuticals | $10.35 | −3.41% | −28.9% | −21.6% | −135.8% | — | $301.3M | Compare |
| ARCTArcturus Therapeutics Holdings | $9.83 | −10.88% | +14.7% | −89.5% | −803.8% | — | $279.4M | Compare |
| SPRYARS Pharmaceuticals | $3.05 | −9.76% | −65.5% | +114.2% | −185.2% | — | $303.3M | Compare |
| IRDOpus Genetics | $3.69 | +0.55% | −29.3% | −73.8% | −1072.6% | — | $307.0M | Compare |
No recent articles focused on Vogenx.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
